Our Management, Board Members, Advisors and Founders contribute a wealth of experience in product development, regulatory strategy, commercial positioning, deal making, raising capital and entrepreneurship to the growth of this company. All of us are passionate about the cause to create innovative products in Regenerative Medicine. We are dedicated to building an exciting company that will yield results for shareholders, customers and patients alike.
Joseph P. Connell
Founder and CEO
Joseph has more than 33 years of Pharmaceutical and Biotechnology Sales and Marketing experience. He has advanced knowledge in product development, launch and commercialization strategies for Dermatology, Wound Healing, Cardiology, Infectious Diseases, Gastroenterology, Oncology, Diabetes, Pain Management and Anesthesiology.
His career has been a continuous development of progressive responsibilities including executive positions with major pharmaceutical companies as well as startups. He has had global responsibilities for nasal, pulmonary and aerosol drug delivery, clinical development and manufacturing.
Joseph has founded or co-founded nine companies, one of which is publicly traded on today’s market. He has supplied the expertise for over eighteen years to startup clients to commercialize various technologies for multiple companies. Mr. Connell was instrumental to management for the launch of 25 major pharmaceutical products. He recently served as co-founder and president in a publicly traded regenerative company and CEO and Chairman of a privately held wound healing company before turning his commitment to building OrthoMend Research, Inc.
Maggi Savo, PhD
Vice President Regulatory Affairs and Manufacturing
With a PhD in Biomedical Engineering from The University of Texas Health Science Center in San Antonio, and product development leadership in the cardiovascular, laparoscopic and orthopedic markets, Dr. Savo provides direction for the regulatory and manufacturing requirements at OrthoMend Research, Inc. Dr. Savo is highly experienced in medical device regulatory and manufacturing, both domestically and internationally. Along with a proven track record of success, Dr. Savo functions with the utmost care and concern for safety, functionality and patient care.
Bruce D. Mullen
Chief Commercial Officer
Bruce D. Mullen, Business Development and Chief Commercial Officer (CCO) is a successful entrepreneur, experienced management/sales executive and financial professional with emerging technology organizations, start-up and at risk companies and new venture opportunities. He has significant healthcare industry expertise highlighted by a 35+ year record of success in this and other fields. Additionally, his experience shows demonstrated results with new technologies and early-to-market product development and launches, identifying and nurturing customer and partner relationships and other critical business essentials.
Peter I. Lelkes, PhD
Chief Scientific Advisor
Dr. Lelkes is the Laura H. Carnell Professor and Founding Chair of the Department of Bioengineering in the College of Engineering at Temple University and the Inaugural Director of the Institute for Regenerative Medicine and Engineering (TIME) at Temple University’s School of Medicine. At Temple, Prof. Lelkes directed an interdisciplinary program in tissue engineering and regenerative medicine, focusing on nanotechnology-based biomaterials and soft tissue engineering, employing developmental biological principles to enhance the tissue-specific differentiation of embryonic and adult stem cells. Dr. Lelkes has organized several Keystone conferences and published more than 160 peer-reviewed papers and 45 book chapters and made more than 400 presentations nationally and internationally.
Dr. Lelkes’s basic and translational research has been supported by federal (NIH, NSF, NASA, DOE) and state funding agencies (NTI and Dept of Commerce, Tobacco Settlement Funds) and private foundations, including the Coulter Foundation. Most recently, Dr. Lelkes has been named Director of the Surgical Engineering Enterprise, one of the major initiatives of the strategic plan of Temple University’s College of Medicine. In addition, Dr. Lelkes has been the team leader for tissue engineering at the Nanotechnology Institute of Southeastern Pennsylvania (NTI) and is the Co-Director of PATRIC, the Pennsylvania Advanced Textile Research and Innovation Center, focusing on BioNanoTextiles and Stem Cell Biology.
Bruce D. Browner, MD, MHCM, FACS
Member, Strategic Advisory Board
Dr. Browner’s current position is Adjunct Professor in the Departments of Orthopaedic Surgery at the Duke University Medical Center and Wake Forest University School of Medicine. Dr. Browner received his MD Degree at the State University of New York Downstate Medical Center and his Orthopaedic Training at Albany Medical Center. He has been on the faculty at the University of Maryland, University of Texas (Houston), and University of Connecticut. He has served twenty-seven years in the roles of Division Chief, Department Chair and Residency Program Director.
He is Past President of Orthopaedic Trauma Association, a member of the: American Orthopaedic Association, American Association for the Surgery of Trauma, Association for the Advancement of Automotive Medicine, Musculoskeletal Infection Society, and Association for Safe International Road Travel.
Dr. Browner is lead editor for Skeletal Trauma, the 5th edition, published 12/15/14, and also co-editor Musculoskeletal Emergencies, 1st edition published 2013. He has also been Editor in Chief for Techniques in Orthopaedics for twenty-four years. He served as co-editor for the American Academy of Orthopaedic Surgeons, Emergency Care and Transport of the Sick and Injured, 7th and 8th editions.
He has been engaged as a consultant by the American Board of Orthopaedic Surgery to work on an initiative entitled “Essential Knowledge, Skills and Behavior for Orthopaedic Residents” that is exploring the possible development of a standardized Curriculum and assessment methods for orthopaedic training similar to those that are now used or developed in the other English speaking countries He is also assisting the Trauma Committee of the Society of Military orthopaedic Surgeons with a similar effort to create a standardized curriculum and validation methods to assure competency of surgeons in the care of wounded warriors. As an orthopaedic faculty at Duke, he is working with the residency program directors on assessment methodology for the redesign of the orthopaedic residency program.
Sandra G. Stoneman, Esq.
Sandra G. Stoneman is co-head of the firm’s Life Sciences Practice Group. Ms. Stoneman concentrates her practice in the areas of general corporate, mergers and acquisitions, venture capital and private equity and securities law, representing entrepreneurs, emerging companies, public companies and investors. She also serves as outside general counsel to emerging healthcare and technology companies, representing them in various matters from formation through exit, including organization and structure matters, founder relationships, financing arrangements, strategic, licensing and partnering transactions, clinical trial and other research agreements and commercial and operational arrangements. Additionally, Ms. Stoneman advises management and boards of directors on corporate governance matters.
Ms. Stoneman is an adjunct professor at Temple Law School, teaching a Practicum on entrepreneur legal support.
Ms. Stoneman is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and is a summa cum laude graduate of the State University of New York at Binghamton.